

James W Catto

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8516026/james-w-catto-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

242
papers

14,249
citations

57
h-index

115
g-index

320
ext. papers

18,184
ext. citations

7.5
avg, IF

6.37
L-index

#	Paper	IF	Citations
242	10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 1415-1424	59.2	1451
241	Epidemiology and risk factors of urothelial bladder cancer. <i>European Urology</i> , 2013 , 63, 234-41	10.2	1180
240	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. <i>Cell</i> , 2017 , 171, 540-556	37.5	961
239	Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 1425-1437	59.2	655
238	Systematic review of complications of prostate biopsy. <i>European Urology</i> , 2013 , 64, 876-92	10.2	564
237	MicroRNA in prostate, bladder, and kidney cancer: a systematic review. <i>European Urology</i> , 2011 , 59, 671-81	10.2	355
236	Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. <i>European Urology</i> , 2018 , 74, 784-795	10.2	265
235	Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomy. <i>European Urology</i> , 2015 , 67, 376-401	10.2	260
234	Distinct microRNA alterations characterize high- and low-grade bladder cancer. <i>Cancer Research</i> , 2009 , 69, 8472-81	10.1	260
233	Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2903-10	2.2	249
232	Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). <i>European Urology</i> , 2018 , 74, 294-306	10.2	176
231	The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. <i>European Urology</i> , 2016 , 70, 458-66	10.2	175
230	Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. <i>European Urology</i> , 2015 , 68, 238-53	10.2	168
229	Enhanced Recovery after Urological Surgery: A Contemporary Systematic Review of Outcomes, Key Elements, and Research Needs. <i>European Urology</i> , 2016 , 70, 176-187	10.2	167
228	Epigenetics in prostate cancer: biologic and clinical relevance. <i>European Urology</i> , 2011 , 60, 753-66	10.2	164
227	Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. <i>BMJ, The</i> , 2012 , 344, d7894	5.9	163
226	Systematic review and cumulative analysis of oncologic and functional outcomes after robot-assisted radical cystectomy. <i>European Urology</i> , 2015 , 67, 402-22	10.2	158

225	Hexyl aminolevulinic acid-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. <i>European Urology</i> , 2013 , 64, 624-38	10.2	156
224	Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016 , 69, 693-703	10.2	153
223	Promoter hypermethylation identifies progression risk in bladder cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 2046-53	12.9	150
222	The mutational landscape of prostate cancer. <i>European Urology</i> , 2013 , 64, 567-76	10.2	144
221	Genomic Predictors of Outcome in Prostate Cancer. <i>European Urology</i> , 2015 , 68, 1033-44	10.2	136
220	Defining a standard set of patient-centered outcomes for men with localized prostate cancer. <i>European Urology</i> , 2015 , 67, 460-7	10.2	136
219	Contemporary Occupational Carcinogen Exposure and Bladder Cancer: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2015 , 1, 1282-90	13.4	135
218	Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. <i>Lancet, The</i> , 2020 , 395, 1268-1277	40	133
217	Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. <i>Clinical Cancer Research</i> , 2014 , 20, 1990-2000	12.9	132
216	Behavior of urothelial carcinoma with respect to anatomical location. <i>Journal of Urology</i> , 2007 , 177, 1715-20	12.9	131
215	Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel. <i>European Urology</i> , 2015 , 67, 363-75	10.2	128
214	Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. <i>Clinical Cancer Research</i> , 2007 , 13, 1720-5	12.9	126
213	Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2018 , 73, 925-933	10.2	114
212	Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. <i>Oncogene</i> , 2003 , 22, 8699-706	9.2	113
211	Early detection of prostate cancer: European Association of Urology recommendation. <i>European Urology</i> , 2013 , 64, 347-54	10.2	106
210	iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression. <i>Journal of Proteome Research</i> , 2008 , 7, 897-907	5.6	95
209	FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. <i>European Urology</i> , 2009 , 55, 650-7	10.2	90
208	Enhanced Recovery After Robot-assisted Radical Cystectomy: EAU Robotic Urology Section Scientific Working Group Consensus View. <i>European Urology</i> , 2016 , 70, 649-660	10.2	90

207	Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy. <i>European Urology</i> , 2018 , 73, 363-371	10.2	90
206	Intratour heterogeneity in urologic cancers: from molecular evidence to clinical implications. <i>European Urology</i> , 2015 , 67, 729-37	10.2	86
205	Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 1287-96	12.9	82
204	Correction to: Meeting abstracts from the 4th International Clinical Trials Methodology Conference (ICTMC) and the 38th Annual Meeting of the Society for Clinical Trials. <i>Trials</i> , 2018 , 19,	2.8	78
203	Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review. <i>European Urology</i> , 2018 , 73, 738-748	10.2	77
202	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). <i>European Urology</i> , 2019 , 76, 790-813	10.2	76
201	Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. <i>European Urology</i> , 2018 , 74, 357-368	10.2	72
200	Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. <i>European Urology</i> , 2020 , 78, 29-42	10.2	71
199	Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. <i>European Urology</i> , 2020 , 77, 101-109	10.2	70
198	Application of artificial intelligence to the management of urological cancer. <i>Journal of Urology</i> , 2007 , 178, 1150-6	2.5	69
197	Molecular mechanisms of cisplatin resistance in bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 271-81	3.5	68
196	Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. <i>International Journal of Cancer</i> , 2008 , 122, 952-6	7.5	66
195	Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. <i>Journal of Pathology</i> , 2006 , 209, 336-43	9.4	66
194	Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2020 , 78, 402-414	10.2	65
193	Multiparametric MRI of the bladder: inter-observer agreement and accuracy with the Vesical Imaging-Reporting and Data System (VI-RADS) at a single reference center. <i>European Radiology</i> , 2019 , 29, 5498-5506	8	64
192	Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability. <i>International Journal of Cancer</i> , 2003 , 105, 484-90	7.5	64
191	Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study. <i>Lancet Oncology</i> , 2019 , 20, 436-447	21.7	59
190	Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions. <i>Human Pathology</i> , 2004 , 35, 1385-91	3.7	59

189	Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks. <i>Clinical Cancer Research</i> , 2003 , 9, 4172-7	12.9	59
188	Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer. <i>European Urology</i> , 2012 , 62, 1088-96	10.2	57
187	Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer. <i>European Urology</i> , 2013 , 63, 145-54	10.2	56
186	Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. <i>BMJ Open</i> , 2018 , 8, e022899	3	55
185	European Association of Urology (@Uroweb) recommendations on the appropriate use of social media. <i>European Urology</i> , 2014 , 66, 628-32	10.2	54
184	Robot-assisted radical cystectomy with intracorporeal urinary diversion versus open radical cystectomy (iROC): protocol for a randomised controlled trial with internal feasibility study. <i>BMJ Open</i> , 2018 , 8, e020500	3	54
183	Precision surgery and genitourinary cancers. <i>European Journal of Surgical Oncology</i> , 2017 , 43, 893-908	3.6	53
182	Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. <i>European Urology</i> , 2019 , 76, 142-150	10.2	51
181	Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours. <i>World Journal of Urology</i> , 2013 , 31, 21-9	4	51
180	Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. <i>Journal of Urology</i> , 2006 , 175, 2323-30	2.5	51
179	An evaluation of morphological and functional multi-parametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer. <i>European Radiology</i> , 2017 , 27, 3759-3766	8	50
178	Identification of differentially expressed long noncoding RNAs in bladder cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 5311-21	12.9	50
177	Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review. <i>European Urology</i> , 2015 , 67, 876-88	10.2	50
176	Regulation of neutrophil senescence by microRNAs. <i>PLoS ONE</i> , 2011 , 6, e15810	3.7	50
175	Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. <i>European Urology</i> , 2020 , 77, 320-330	10.2	50
174	Critical Review of Outcomes from Radical Cystectomy: Can Complications from Radical Cystectomy Be Reduced by Surgical Volume and Robotic Surgery?. <i>European Urology Focus</i> , 2016 , 2, 19-29	5.1	47
173	Robot-assisted radical cystectomy and urinary diversion: technical recommendations from the Pasadena Consensus Panel. <i>European Urology</i> , 2015 , 67, 423-31	10.2	47
172	Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. <i>European Urology</i> , 2013 , 63, 1049-58	10.2	47

171	Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. <i>European Urology Oncology</i> , 2020 , 3, 306-315	6.7	46
170	Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A. <i>Prostate</i> , 2007 , 67, 1761-9	4.2	46
169	A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. <i>BJU International</i> , 2008 , 101, 1448-53	5.6	44
168	Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review. <i>European Urology Oncology</i> , 2019 , 2, 265-273	6.7	44
167	Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer. <i>Prostate</i> , 2005 , 65, 322-30	4.2	43
166	Improving Staging in Bladder Cancer: The Increasing Role of Multiparametric Magnetic Resonance Imaging. <i>European Urology Focus</i> , 2016 , 2, 113-121	5.1	42
165	Luzp4 defines a new mRNA export pathway in cancer cells. <i>Nucleic Acids Research</i> , 2015 , 43, 2353-66	20.1	39
164	KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients. <i>American Journal of Pathology</i> , 2011 , 179, 540-6	5.8	39
163	Online Professionalism-2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. <i>European Urology</i> , 2018 , 74, 644-650	10.2	38
162	Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 1078-87	2.8	37
161	The patientsPexperience of a bladder cancer diagnosis: a systematic review of the qualitative evidence. <i>Journal of Cancer Survivorship</i> , 2017 , 11, 453-461	5.1	37
160	Global epigenetic profiling in bladder cancer. <i>Epigenomics</i> , 2011 , 3, 35-45	4.4	36
159	BPH and prostate cancer risk. <i>Indian Journal of Urology</i> , 2014 , 30, 214-8	0.8	35
158	Disease specific mortality in patients with low risk bladder cancer and the impact of cystoscopic surveillance. <i>Journal of Urology</i> , 2013 , 189, 828-33	2.5	34
157	The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression. <i>European Urology</i> , 2010 , 57, 398-406	10.2	34
156	Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. <i>European Urology</i> , 2018 , 74, 597-608	10.2	33
155	Staging the Host: Personalizing Risk Assessment for Radical Cystectomy Patients. <i>European Urology Oncology</i> , 2018 , 1, 292-304	6.7	32
154	Urology Tag Ontology Project: Standardizing Social Media Communication Descriptors. <i>European Urology</i> , 2016 , 69, 183-5	10.2	31

153	The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer: time to change treatment paradigm?. <i>Cancer</i> , 2012 , 118, 5525-34	6.4	31
152	A miRNA-145/TGF- β negative feedback loop regulates the cancer-associated fibroblast phenotype. <i>Carcinogenesis</i> , 2018 , 39, 798-807	4.6	30
151	Markers for detection of prostate cancer. <i>Cancers</i> , 2010 , 2, 1125-54	6.6	30
150	Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. <i>European Urology</i> , 2020 , 78, 209-220	10.2	29
149	Integrated epigenome profiling of repressive histone modifications, DNA methylation and gene expression in normal and malignant urothelial cells. <i>PLoS ONE</i> , 2012 , 7, e32750	3.7	28
148	Health-related quality of life after treatment for bladder cancer in England. <i>British Journal of Cancer</i> , 2018 , 118, 1518-1528	8.7	28
147	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2017 , 35, 355-365	4	27
146	Next-generation RNA sequencing of archival formalin-fixed paraffin-embedded urothelial bladder cancer. <i>European Urology</i> , 2014 , 66, 982-6	10.2	27
145	Neuro-fuzzy modeling: an accurate and interpretable method for predicting bladder cancer progression. <i>Journal of Urology</i> , 2006 , 175, 474-9	2.5	27
144	Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. <i>European Urology</i> , 2019 , 76, 368-380	10.2	26
143	Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. <i>European Urology</i> , 2017 , 71, 381-388	10.2	25
142	Telemedicine and Smart Working: Recommendations of the European Association of Urology. <i>European Urology</i> , 2020 , 78, 812-819	10.2	24
141	The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future. <i>European Urology</i> , 2020 , 78, 731-742	10.2	23
140	Long-term Outcomes from Re-resection for High-risk Non-muscle-invasive Bladder Cancer: A Potential to Rationalize Use. <i>European Urology Focus</i> , 2019 , 5, 650-657	5.1	23
139	Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project. <i>Annals of Oncology</i> , 2015 , 26, 2392-8	10.3	22
138	MicroRNA-99a and 100 mediated upregulation of FOXA1 in bladder cancer. <i>Oncotarget</i> , 2014 , 5, 6375-86	5.3	22
137	Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer. <i>JCO Global Oncology</i> , 2020 , 6, 1248-1257	3.7	22
136	Evaluating patient-reported outcome measures (PROMs) for bladder cancer: a systematic review using the Consensus-based Standards for the selection of health Measurement INstruments (COSMIN) checklist. <i>BJU International</i> , 2018 , 122, 760-773	5.6	21

135	Multidomain Quantitative Recovery Following Radical Cystectomy for Patients Within the Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion Versus Open Radical Cystectomy Randomised Controlled Trial: The First 30 Patients. <i>European Urology</i> , 2018 , 74, 531-534	10.2	21
134	Low frequency of epigenetic events in urothelial tumors in young patients. <i>Journal of Urology</i> , 2010 , 184, 459-63	2.5	20
133	Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. <i>Clinical Cancer Research</i> , 2009 , 15, 3150-5	12.9	19
132	Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. <i>European Urology</i> , 2020 , 78, 719-730	10.2	18
131	An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. <i>Journal of Clinical Epidemiology</i> , 2018 , 99, 75-83	5.7	18
130	Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT. <i>Health Technology Assessment</i> , 2018 , 22, 1-96	4.4	18
129	Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study. <i>BMJ Open</i> , 2017 , 7, e017913	3	17
128	Epigenetic regulation of microRNA expression in cancer. <i>Methods in Molecular Biology</i> , 2011 , 676, 165-84	4.4	17
127	Systematic Review and Meta-Analysis of Vesical Imaging-Reporting and Data System (VI-RADS) Inter-Observer Reliability: An Added Value for Muscle Invasive Bladder Cancer Detection. <i>Cancers</i> , 2020 , 12,	6.6	17
126	Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study. <i>European Urology</i> , 2008 , 53, 777-84	10.2	16
125	Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis. <i>European Urology</i> , 2020 , 77, 583-598	10.2	16
124	Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. <i>European Urology</i> , 2021 , 80, 703-711	10.2	16
123	Bladder cancer in 2012: Challenging current paradigms. <i>Nature Reviews Urology</i> , 2013 , 10, 67-8	5.5	15
122	DNA methylation and immunohistochemical analysis of the S100A4 calcium binding protein in human prostate cancer. <i>Prostate</i> , 2007 , 67, 341-7	4.2	15
121	EORTC risk tables - their usefulness in the assessment of recurrence and progression risk in non-muscle-invasive bladder cancer in Polish patients. <i>Urologia Polska</i> , 2013 , 66, 14-20		15
120	Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial 2020 , 8,		14
119	Molecular subtyping of bladder cancer using Kohonen self-organizing maps. <i>Cancer Medicine</i> , 2014 , 3, 1225-34	4.8	14
118	Simultaneous augmentation cystoplasty is associated with earlier rather than increased artificial urinary sphincter infection. <i>Journal of Urology</i> , 2005 , 173, 1237-41	2.5	14

117	The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. <i>BJU International</i> , 2020 , 125, 506-514	5.6	14
116	Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. <i>European Urology</i> , 2016 , 69, 186-90	10.2	13
115	VI-RADS Scoring Criteria for Alternative Risk-adapted Strategies in the Management of Bladder Cancer During the COVID-19 Pandemic. <i>European Urology</i> , 2020 , 78, e18-e20	10.2	13
114	Bladder-sparing treatment in MIBC: where do we stand?. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019 , 71, 101-112	4.4	13
113	Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes. <i>European Urology</i> , 2021 , 79, 621-632	10.2	13
112	Quality Indicators for Bladder Cancer Services: A Collaborative Review. <i>European Urology</i> , 2020 , 78, 43-59	10.2	13
111	A New Fuzzy Modeling Framework for Integrated Risk Prognosis and Therapy of Bladder Cancer Patients. <i>IEEE Transactions on Fuzzy Systems</i> , 2018 , 26, 1565-1577	8.3	13
110	The contemporary landscape of occupational bladder cancer within the United Kingdom: a meta-analysis of risks over the last 80 years. <i>BJU International</i> , 2017 , 119, 100-109	5.6	12
109	Specificity of the Metallothionein-1 Response by Cadmium-Exposed Normal Human Urothelial Cells. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	12
108	CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer. <i>BJU International</i> , 2020 , 125, 817-826	5.6	12
107	Occupation and Bladder Cancer Phenotype: Identification of Workplace Patterns That Increase the Risk of Advanced Disease Beyond Overall Incidence. <i>European Urology Focus</i> , 2018 , 4, 725-730	5.1	12
106	Clinically localised prostate cancer is microsatellite stable. <i>BJU International</i> , 2007 , 99, 1031-5	5.6	12
105	Altered RECQL5 expression in urothelial bladder carcinoma increases cellular proliferation and makes RECQL5 helicase activity a novel target for chemotherapy. <i>Oncotarget</i> , 2016 , 7, 76140-76150	3.3	12
104	Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. <i>World Journal of Urology</i> , 2020 , 38, 1959-1968	4	12
103	Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 202-214	2.2	12
102	Noncoding RNA in bladder cancer: a specific focus upon high-risk nonmuscle invasive disease. <i>Current Opinion in Urology</i> , 2014 , 24, 506-11	2.8	11
101	Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. <i>European Urology Oncology</i> , 2021 , 4, 12-19	6.7	11
100	E-cigarettes and Urologic Health: A Collaborative Review of Toxicology, Epidemiology, and Potential Risks. <i>European Urology</i> , 2017 , 71, 915-923	10.2	10

99	Urinary, bowel and sexual health in older men from Northern Ireland. <i>BJU International</i> , 2018 , 122, 845-857	5.7	10
98	Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer. <i>BJU International</i> , 2018 , 122, 970-977	5.6	10
97	Snapshot of transurethral resection of bladder tumours in the United Kingdom Audit (STUKA). <i>BJU International</i> , 2013 , 112, 930-5	5.6	10
96	Occupational exposure to crack detection dye penetrants and the potential for bladder cancer. <i>Occupational and Environmental Medicine</i> , 2012 , 69, 300-1	2.1	10
95	Critical analysis of quality of life and cost-effectiveness of enhanced recovery after surgery (ERAS) for patientB undergoing urologic oncology surgery: a systematic review. <i>World Journal of Urology</i> , 2020 , 1	4	9
94	A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. <i>Journal of Clinical Epidemiology</i> , 2018 , 96, 35-46	5.7	9
93	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. <i>Health Technology Assessment</i> , 2020 , 24, 1-176	4.4	9
92	Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study. <i>European Urology</i> , 2021 , 80, 12-15	10.2	9
91	A Comparative Analysis of the Influence of Gender, Pathway Delays, and Risk Factor Exposures on the Long-term Outcomes of Bladder Cancer. <i>European Urology Focus</i> , 2015 , 1, 82-89	5.1	8
90	New Gleason grading system: Statement from the Editors of six journals. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 253	2.8	8
89	Prostate cancer proteomics: The urgent need for clinically validated biomarkers. <i>Proteomics - Clinical Applications</i> , 2009 , 3, 197-212	3.1	7
88	Pancreatic debridement in a district general hospital--viable or vulnerable?. <i>Annals of the Royal College of Surgeons of England</i> , 2002 , 84, 309-13	1.4	7
87	SPIRE - combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial. <i>Trials</i> , 2018 , 19, 216	2.8	6
86	Less is more: artificial intelligence and gene-expression arrays. <i>Lancet, The</i> , 2004 , 364, 2003-4	4.0	6
85	A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guérin (BCG) therapy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS603-TPS603	2.2	6
84	Biomarkers predicting oncological outcomes of high-risk non-muscle-invasive bladder cancer. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020 , 72, 265-278	4.4	6
83	Islam and the Urinary Stoma: A Contemporary Theological and Urological Dilemma. <i>European Urology Focus</i> , 2019 , 5, 301-305	5.1	6
82	Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes. <i>European Urology Focus</i> , 2020 , 6, 1226-1232	5.1	6

81	Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE). <i>Clinical Cancer Research</i> , 2021 , 27, 1882-1892	12.9	6
80	Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom. <i>European Urology</i> , 2019 , 76, 228-237	10.2	5
79	Identification and diagnostic performance of a small RNA within the PCA3 and BMCC1 gene locus that potentially targets mRNA. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 268-75	4	5
78	Reply to Andrea Necchi, Antonella Messina, and Alberto Briganti Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). <i>Eur Urol</i> 2018;74:294-306. <i>European Urology</i> , 2018 , 74, e109	10.2	5
77	The Use of Proteomics in Urological Research. <i>EAU Update Series</i> , 2005 , 3, 171-179		5
76	Optimal Dissemination of Scientific Manuscripts via Social Media: A Prospective Trial Comparing Visual Abstracts Versus Key Figures in Consecutive Original Manuscripts Published in European Urology.. <i>European Urology</i> , 2022 ,	10.2	5
75	Robotic intracorporeal urinary diversion: practical review of current surgical techniques. <i>Minerva Urology and Nephrology</i> , 2017 , 69, 14-25	2.3	5
74	A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 811-820	4.9	5
73	The Road to Cystectomy: Who, When and Why?. <i>EAU Update Series</i> , 2005 , 3, 118-128		4
72	Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes. <i>PLoS ONE</i> , 2020 , 15, e0239338	3.7	4
71	The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer. <i>British Journal of Cancer</i> , 2020 , 123, 1063-1070	8.7	4
70	Prehabilitation Exercise Before Urologic Cancer Surgery: A Systematic and Interdisciplinary Review. <i>European Urology</i> , 2021 ,	10.2	4
69	Management of Patients with Normal Cystoscopy but Positive Cytology or Urine Markers. <i>European Urology Oncology</i> , 2020 , 3, 548-554	6.7	4
68	Impact of Anaesthetist Volume on Radical Cystectomy Outcomes. <i>European Urology Focus</i> , 2021 , 7, 117-123	5.23	4
67	Bladder cancer: shedding light on the most promising investigational drugs in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 837-855	5.9	4
66	The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer - a multicentre observational study. <i>BJU International</i> , 2021 , 128, 440-450	5.6	4
65	The Impact of Centralised Services on Metric Reflecting High-quality Performance: Outcomes from 1110 Consecutive Radical Cystectomies at a Single Centre. <i>European Urology Focus</i> , 2021 , 7, 554-565	5.1	3
64	Reply to Mark C. Kendall Letter to the Editor re: Karl H. Pang, Ruth Groves, Suresh Venugopal, Aidan P. Noon, James W.F. Catto. Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy. <i>Eur Urol</i> 2018;73:363-71. <i>European Urology</i> , 2018 , 74, e66	10.2	3

63	Old and New Urinary Markers: Which One is the PSA for Bladder Cancer?. <i>European Urology Supplements</i> , 2008 , 7, 422-425	0.9	3
62	Response to guadecitabine (SGI-110) combined with cisplatin and gemcitabine (GCG) in platinum refractory germ cell tumors (GCTs).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17057-e17057	2.2	3
61	Replacing TURBT with mpMRI for staging MIBC: Pilot data from the BladderPath study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 446-446	2.2	3
60	Epidemiology and Risk Factors for Upper Urinary Urothelial Cancers 2015 , 1-30		3
59	Life and bladder cancer: protocol for a longitudinal and cross-sectional patient-reported outcomes study of Yorkshire (UK) patients. <i>BMJ Open</i> , 2019 , 9, e030850	3	3
58	Robot-assisted versus open cystectomy in the RAZOR trial. <i>Lancet, The</i> , 2019 , 393, 644-645	4.0	2
57	Comparing open-radical cystectomy and robot-assisted radical cystectomy: current status and analysis of the evidence. <i>Current Opinion in Urology</i> , 2020 , 30, 400-406	2.8	2
56	IDENTIFY: The investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer: A multicentre cohort study. <i>International Journal of Surgery Protocols</i> , 2020 , 21, 8-12	1.1	2
55	Consensus guidelines for reporting prostate cancer Gleason Grade. <i>BJU International</i> , 2016 , 118, E1-2	5.6	2
54	Editorial Statement on Gleason Scoring for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 95, 1092	4	2
53	Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study. <i>Journal of Clinical Epidemiology</i> , 2019 , 113, 200-213	5.7	2
52	MicroRNA and urothelial cell carcinoma. <i>BJU International</i> , 2014 , 113, 811-2	5.6	2
51	Exercise interventions for men with prostate cancer. <i>The Cochrane Library</i> , 2015 ,	5.2	2
50	The changing face of prostate cancer: can gains in epigenetic knowledge translate into improvements in clinical care?. <i>Journal of Molecular Medicine</i> , 2006 , 84, 883-5	5.5	2
49	DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostateA randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS385-TPS385	2.2	2
48	Is Social Media Worth the Risk for Health Care Professionals?. <i>European Urology Focus</i> , 2020 , 6, 427-429	5.1	2
47	Does the robot have a role in radical cystectomy?. <i>BJU International</i> , 2019 , 123, 380-382	5.6	2
46	Quantification of Urology Related Twitter Traffic Activity through a Standardized List of Social Media Communication Descriptors. <i>Urology Practice</i> , 2017 , 4, 349-354	0.8	1

45	Reply to Charalampos Fragkoulis, Georgios Papadopoulos, and Konstantinos Ntoumas Letter to the Editor re: Francesco Del Giudice, Giovanni Barchetti, Ettore De Berardinis, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Evaluation of a short RNA within Prostate Cancer Gene 3 in the predictive role for future cancer using non-malignant prostate biopsies. <i>PLoS ONE</i> , 2017 , 12, e0175070	10.2	1
44	Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer. <i>European Urology</i> , 2019 , 76, 872-873	10.2	1
43	Targeting chemotherapy to advanced bladder cancer patients most likely to benefit. <i>Future Oncology</i> , 2010 , 6, 193-6	3.6	1
42	Haematuria. <i>Surgery</i> , 2010 , 28, 589-593	0.3	1
41	Haematuria. <i>Surgery</i> , 2008 , 26, 150-153	0.3	1
40	Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center: in regard to Kotwal et al. (Int J Radiat Oncol Biol Phys 2008;70:456-463). <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 71, 1601-2; author reply 1602	4	1
39	Safety and exceptional immunogenicity of novel 5T4 viral vectored vaccination regimes in early stage prostate cancer: a phase I clinical trial		1
38	Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial. <i>BMJ Open</i> , 2020 , 10, e036024	3	1
37	Radical Cystectomy in England from 2013 to 2019 on 12,644 patients: An analysis of national trends and comparison of surgical approaches using Hospital Episode Statistics data.. <i>BJUI Compass</i> , 2021 , 2, 338-347	0.9	1
36	Reply to Wentao Liu, Xiaokun Zhao, Zhaohui Zhong Letter to the Editor re: Marcus G. Cumberbatch, Matteo Rota, James W.F. Catto, Carlo La Vecchia. The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. <i>Eur Urol</i> 2016;70:458-66. <i>European Urology</i> , 2015 , 70, e106-e107	10.2	1
35	Reply to Jeremy Y.C. Teoh, Thomas R.W. Herrmann, and Marek Babjuk Letter to the Editor re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting and Data System). <i>Eur Urol</i> 2018;74:224-231. <i>European Urology</i> , 2018 , 75, e28-e29	10.2	1
34	Re: Comprehensive Molecular Characterization of Muscle Invasive Bladder Cancer. <i>European Urology</i> , 2018 , 73, 479-480	10.2	1
33	How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder?. <i>European Urology Oncology</i> , 2021 , 4, 663-669	6.7	0
32	Time to change our approach to high-risk nonmuscle-invasive bladder cancer management in the United Kingdom? Observations from the British Association of Urological Surgeons Cancer Registry. <i>BJU International</i> , 2010 , 106, 593-4	5.6	0
31	Reply to Gianluca Giannarini, Vincenzo Ficarra, and Claudio Valotto Letter to the Editor re: Stephen B. Williams, Marcus G.K. Cumberbatch, Ashish M. Kamat, et al. Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. <i>Eur Urol</i> in press.	10.2	0
30	The Scottish Bladder Cancer Quality Performance Indicators Influencing Outcomes, Prognosis, and Surveillance (Scot BC Quality OPS) Clinical Project. <i>European Urology Focus</i> , 2021 , 7, 905-908	5.1	0
29	Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2021 , 5, 70-70	6.7	0
28			

27	Defining Factors Associated with High-quality Surgery Following Radical Cystectomy: Analysis of the British Association of Urological Surgeons Cystectomy Audit. <i>European Urology Open Science</i> , 2021 , 33, 1-10	0.9	0
26	A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D + EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA).. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS579-TPS579	2.2	0
25	In Memory of John Fitzpatrick. <i>European Urology</i> , 2014 , 66, 604	10.2	
24	Reply to Lars Egevad, Hemamali Samaratunga, John R. Srigley, Brett DelahuntB Letter to the Editor re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. <i>Eur Urol</i> 2016;70:1. <i>European Urology</i> , 2017 , 71, e54	10.2	
23	Theepigenetic profile of bladder cancer323-337		
22	Words of wisdom. Re: Comorbidity and mortality results from a randomised prostate cancer screening trial. <i>European Urology</i> , 2011 , 60, 867	10.2	
21	Words of wisdom. Re: Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. <i>European Urology</i> , 2009 , 55, 1487-8	10.2	
20	Urological diagnosis [history and investigations. <i>Surgery</i> , 2008 , 26, 154-160	0.3	
19	The Role of Genetic Instability in the Pathogenesis and Progression of Urothelial Carcinoma. <i>EAU Update Series</i> , 2005 , 3, 180-188		
18	Assessing the patient with a urological problem. <i>Foundation Years</i> , 2005 , 1, 1-7		
17	Phase I/II open label nonrandomized safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 immunotherapy in combination with PD-1 checkpoint blockade in intermediate-risk localized or locally advanced prostate cancer and advanced metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS3170-TPS3170	2.2	
16	High Dimensionality and Scaling-up Performance of RBF Models with Application to Healthcare Informatics. <i>International Journal of Machine Learning and Computing</i> , 2015 , 5, 62-67	1.8	
15	Measuring Patient Compliance With Remote Monitoring Following Discharge From Hospital After Major Surgery (DREAMPath): Protocol for a Prospective Observational Study.. <i>JMIR Research Protocols</i> , 2022 , 11, e30638	2	
14	In Reply to Samaratunga et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 1127-1128		
13	The Use of Biomarkers to Manage Men with Metastatic Prostate Cancer: One Day, But Not Yet. <i>European Urology Focus</i> , 2016 , 2, 467-468	5.1	
12	Re: Samaratunga et al: Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. <i>Urology</i> , 2016 , 96, 179	1.6	
11	Urethral recurrence after radical cystoprostatectomy: Experience from a high-volume tertiary referral centre. <i>Journal of Clinical Urology</i> , 2021 , 14, 238-245	0.2	
10	DNA methyltransferase inhibitor guadecitabine combined with cisplatin and gemcitabine chemotherapy (SPIRE): Randomized expansion phase as neoadjuvant therapy for bladder urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 447-447	2.2	

- 9 DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.. *Journal of Clinical Oncology*, **2021**, 39, TPS266-TPS266 2.2
- 8 DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.. *Journal of Clinical Oncology*, **2022**, 40, TPS284-TPS284 2.2
- 7 Real-world evidence from a single U.K. cancer center for atezolizumab in second-line setting in advanced urothelial cancer: Moving beyond clinical trials.. *Journal of Clinical Oncology*, **2022**, 40, 461-461^{2.2}
- 6 Reply to Benjamin Davies, Keith Kowalczyk RE: Zachary Klaassen, Emily Vertosick, Andrew J. Vickers, et al. Optimal Dissemination of Scientific Manuscripts via Social Media: A Prospective Trial Comparing Visual Abstracts Versus Key Figures in Consecutive Original Manuscripts. *Eur Urol*. In press. <https://doi.org/10.1016/j.eururo.2022.01.041>. *European Urology*, **2022**, 82, e12-e12 10.2
- 5 Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes **2020**, 15, e0239338
- 4 Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes **2020**, 15, e0239338
- 3 Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes **2020**, 15, e0239338
- 2 Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes **2020**, 15, e0239338
- 1 Case of the month from the University of Sheffield, UK : Expediting definitive treatment in patients with invasive bladder cancer: an MRI -guided pathway. *BJU International*, **2022**, 129, 691-694 5.6